Open AccessTenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients
Author(s) -
Danhong Yang,
Yuan-Jun Xie,
Nan Zhao,
Hongying Pan,
Mingwei Li,
Haijun Huang
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i9.2746
Subject(s) - adefovir , lamivudine , medicine , gastroenterology , hepatitis b , hepatitis b virus , chronic hepatitis , combination therapy , virology , virus
To assess the efficacy of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM)-resistant patients with a suboptimal response to LAM plus adefovir (ADV).